StockReport.com is a 7:00 PM newsletter with a pertinent stock report every day, plus the lates market news.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.
The company’s product offerings center around several core platforms. Captisol® is a chemically modified cyclodextrin used to improve the solubility, stability and delivery of small-molecule drug candidates. Ligand’s research services portfolio includes antibody discovery and optimization through its OmniAb™ platform, as well as absorption, distribution, metabolism and excretion (ADME) testing services provided by its Cyprotex and Absorption Systems subsidiaries. Together, these technologies and services support early- and late-stage drug development programs for a broad range of partners worldwide.
Founded in 1987 and headquartered in San Diego, California, Ligand has grown through strategic acquisitions and collaborations, establishing a global footprint that spans North America, Europe and Asia. The company’s leadership team is led by President and Chief Executive Officer John L. Higgins, whose experience in drug development and corporate transactions has guided Ligand’s transformation into a technology-focused partner for the biopharmaceutical industry. Ligand continues to seek new alliances and in-licensing opportunities aimed at expanding its platform capabilities and royalty revenue streams.
In an economic landscape marked by persistent financial pressures, consumers are increasingly deliberate with their spending. This growing caution has created significant headwinds for many full-price retailers, particularly in sectors such as electronics and high-end apparel, where shoppers are d...
Okta Inc. (NASDAQ: OKTA) stock shot up more than 10% the day after the cybersecurity company delivered a double beat in its Q4 earnings report for its 2026 fiscal year. For shareholders who have been holding the stock, the rally feels overdue. Even with the post-earnings surge, OKTA stock is ...
An estimated 110 million Americans are stuck in rush hour traffic every day, with drivers in highly congested cities losing as much as 100 hours per year to being stuck in traffic jams. That issue does not appear to be getting any better, either. Traffic congestion is on the rise in 70 of t...
IonQ’s (NYSE: IONQ) Q4 2025 earnings report may or may not reveal a shift in the quantum narrative. What it does reveal is some demand for its services and the execution of its strategy, putting it on track to potentially dominate the industry. The strategy has refocused on the chips that dr...